Policy & Regulation
First clinical trial of Alzheimer's disease treatment starts at The National Institute for Health Research University College London Hospitals Clinical Research Facility
11 October 2018 -

The National Institute for Health Research (NIHR) stated that the first clinical trial of a novel approach to modify the progression of Alzheimer's disease has started at the NIHR University College London Hospitals Clinical Research Facility, it was reported yesterday.

The Depletion of serum amyloid P component in Alzheimer's disease (DESPIAD) trial will test if a drug called miridesap removes a protein associated with the disease from the brain and reduces its development. It will explore the safety, tolerability and potential effectiveness of miridesap in patients with Alzheimer's disease. The trial will recruit patients with mild Alzheimer's disease who will each be treated for one year and tested for changes in brain structure and function. The trial will run for around three years. The study is active and open to recruitment but is limited to 100 participants.

This essential trial is funded by The National Institute for Health Research University College London Hospitals Biomedical Research Centre and led by Professor Martin Rossor, NIHR national director for dementia research.

Login
Username:

Password:


Related Headlines